Clinical relevance of diagnosing copd by fixed ratio or lower limit of normal: A systematic review

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 1, 2014, Pages 113-120

  Van Dijk, Wouter D ^a,b   Gupta, Nisha ^b   Tan, Wan C ^c   Bourbeau, Jean ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

COPD; Fixed ratio; Lower limit of normal; Spirometry

Indexed keywords

AIRFLOW; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; EMBASE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SPIROMETRY; SYSTEMATIC REVIEW;

FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; SPIROMETRY; VITAL CAPACITY;

EID: 84893315891     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.781996     Document Type: Review

References (42)

1. Global initiative for chronic obstructrive pulmonary disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. www goldcopd.org. Accessed May 1st 2012.
2. Parr DG. Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. Proc Am Th orac Soc 2011; 8:338-349.
3. Dijk WD, Bemt L, Haak-Rongen S, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res 2011; 12:151.
4. Fromer L. Diagnosing and treating COPD: understanding the challenges and fi nding solutions. Int J Gen Med 2011; 4:729- 739.
5. Guder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal defi nition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 2012; 13:13.
6. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 2007; 131:29-36.
7. Soriano JB, Miravitlles M, Borderias L, et al. [Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. Arch Bronconeumol 2010; 46:522-530.
8. Waked M, Khayat G, Salameh P. Chronic obstructive pulmonary disease prevalence in Lebanon: a cross-sectional descriptive study. Clin Epidemiol 2011; 3:315-323.
9. van Fleteren LE, Franssen FM, Wesseling G, Wouters EF. Th e prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med 2012; 106:871-884.
10. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010; 182:673- 678.
11. Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest 2007; 132:403-409.
12. Joo MJ, Au DH, Fitzgibbon ML, McKell J, Lee TA. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med 2011; 26:1272-1277.
13. Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
14. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://guidance nice org uk/CG101/Guidance/pdf/ English.
15. Accessed May 1st 2012.
16. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassifi cation of airway obstruction. Thorax 2008; 63:1046-1051.
17. Quanjer PH, Enright PL, Miller MR, et al. Th e need to change the method for defi ning mild airway obstruction. Eur Respir J 2011; 37:720-722.
18. Enright PL, Kaminsky DA. Strategies for screening for chronic obstructive pulmonary disease. Respir Care 2003; 48:1194- 1201.
19. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-968.
20. Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC 0.70 in diagnosing COPD: an evidencebased review. Respir Med 2011; 105:907-915.
21. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144:427-437
22. Oxford centre for evidence-based-medicine. Levels of Evidence, version 2001. http:/www.cebm.net. Accessed May 1st 2012.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
24. de Marco R, Accordini S, Anto JM, et al. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med 2009; 180:956-963.
25. Soyseth V, Johnsen HL, Bugge MD, Hetland SM, Kongerud J. Prevalence of airfl ow limitation among employees in Norwegian smelters: a longitudinal study. Occup Environ Med 2011; 68:24-29.
26. Hnizdo E, Glindmeyer HW, Petsonk EL, Enright P, Buist AS. Case defi nitions for chronic obstructive pulmonary disease. COPD 2006; 3:95-100.
27. Glaser S, Schaper C, Obst A et al. Impact of diff erent defi nitions of airfl ow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration 2010; 80:292-300.
28. Rasheed A, Vasudevan V, Shahzad S, Arjomand F, Reminick S. Spirometery interpretation strategies in the diagnosis and severity classifi cation of chronic obstructive pulmonary disease: Discordance between GOLD and ATS/ERS 2005 criteria and treatment implications. Chest 2011; 140(4 meeting abstracts): 888A.
29. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fi xed thresholds identifi es patients at increased risk of mortality. Chest 2012; 141:73-80.
30. Cerveri I, Corsico AG, Accordini S et al. Underestimation of airfl ow obstruction among young adults using FEV1/FVC ?70% as a fi xed cut-off : a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63:1040-1045.
31. Garcia-Rio F, Soriano JB, Miravitlles M et al. Overdiagnosing subjects with COPD using the 0.7 fi xed ratio: correlation with a poor health-related quality of life. Chest 2011; 139:1072-1080.
32. Mannino DM, Buist SA, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defi nes abnormal lung function? Thorax 2007; 62:237-241.
33. Lamprecht B, Schirnhofer L, Kaiser B, Buist SA, Mannino DM, Studnicka M. Subjects with Discordant Airways Obstruction: Lost between Spirometric Defi nitions of COPD. Pulm Med 2011; 2011:780215.
34. Wang Y, Ma D, Xiao W. Misclassifi cation of airway obstruction among elderly population using a fi xed FEV1/FVC ratio ?70% vs. LLN. Respirology 2011; 16(S2):116-117.
35. Izquierdo Alonso JL, De Lucas RP, Rodriguez Glez-Moro JM. Th e Use of the Lower Limit of Normal as a Criterion for COPD Excludes Patients With Increased Morbidity and High Consumption of Health-Care Resources. Arch Bronconeumol 2012; 48:223-228.
36. Akkermans RP, Berrevoets MA, Smeele IJ et al. Lung function decline in relation to diagnostic criteria for airfl ow obstruction in respiratory symptomatic subjects. BMC Pulm Med 2012; 12:12.
37. Lizak MK, Zakliczynski M, Jarosz A, Zembala M, Kalarus Z. Chronic obstructive pulmonary disease diagnosed based on the lower limit of normal does not worsen survival in chronic heart failure patients. Euro J Heart Fail Suppl 2011; 10(S1): S232.
38. Ko FW, Woo J, Tam W et al. Prevalence and risk factors of airfl ow obstruction in an elderly Chinese population. Eur Respir J 2008; 32:1472-1478.
39. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modifi ed GOLD stage 1 COPD. Thorax 2008; 63:768-774.
40. Quanjer PH, Furberg CD. GOLD COPD stage I is not associated with increased risk of death. Respir Med 2012; 106:153.
41. Jordan RE, Miller MR, Lam KB, Cheng KK, Marsh J, Adab P. Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the eff ect of diff erent diagnostic criteria. Analysis of the Health Survey for England. Thorax 2012; 67(7):600-605.
42. Miller MR. Lung function data interpretation. Chest 2012; 141:832-833.